QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: mol.105.021865v1 70/1/366    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Liao, Z. Articles by Pommier, Y. Search for Related Content PubMed PubMed Citation Articles by Liao, Z. Articles by Pommier, Y.

Inhibition of Human Tyrosyl-DNA Phosphodiesterase by Aminoglycoside Antibiotics and Ribosome Inhibitors

Laboratory of Molecular Pharmacology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland

DNA topoisomerase I (Top1) is the target of camptothecin, and novel Top1 inhibitors are in development as anticancer agents. Top1 inhibitors damage DNA by trapping covalent complexes between the Top1 catalytic tyrosine and the 3'-end of the broken DNA. Tyrosyl-DNA phosphodiesterase (Tdp1) can repair Top1-DNA covalent complexes by hydrolyzing the tyrosyl-DNA bond. Inhibiting Tdp1 has the potential to enhance the anticancer activity of Top1 inhibitors (http://discover.nci.nih.gov/pommier/pommier.htm) and to act as antiproliferative agents. In the present study, we report that neomycin inhibits Tdp1 more effectively than the related aminoglycosides paromomycin and lividomycin A. Inhibition of Tdp1 by neomycin is observed both with single- and double-stranded substrates but is slightly stronger with duplex DNA, which is different from aclarubicin, which only inhibits Tdp1 with the double-stranded substrate. Inhibition by neomycin can be overcome with excess Tdp1 and is greatest at low pH. To our knowledge, aminoglycoside antibiotics and the ribosome inhibitors thiostrepton, clindamycin-2-phosphate, and puromycin are the first reported pharmacological Tdp1 inhibitors.

Received for publication December 19, 2005.

Accepted for publication April 17, 2006.

Address correspondence to: Yves Pommier, Bldg. 37, Rm 5068, National Institutes of Health, Bethesda, MD 20892-4255. E-mail: pommier{at}nih.gov

This article has been cited by other articles:

				M. S. Dunstan, P. C. Hang, N. V. Zelinskaya, J. F. Honek, and G. L. Conn Structure of the Thiostrepton Resistance Methyltransferase{middle dot}S-Adenosyl-L-methionine Complex and Its Interaction with Ribosomal RNA J. Biol. Chem., June 19, 2009; 284(25): 17013 - 17020. [Abstract] [Full Text] [PDF]

				C. Marchand, W. A. Lea, A. Jadhav, T. S. Dexheimer, C. P. Austin, J. Inglese, Y. Pommier, and A. Simeonov Identification of phosphotyrosine mimetic inhibitors of human tyrosyl-DNA phosphodiesterase I by a novel AlphaScreen high-throughput assay Mol. Cancer Ther., January 1, 2009; 8(1): 240 - 248. [Abstract] [Full Text] [PDF]

				S. Antony, C. Marchand, A. G. Stephen, L. Thibaut, K. K. Agama, R. J. Fisher, and Y. Pommier Novel high-throughput electrochemiluminescent assay for identification of human tyrosyl-DNA phosphodiesterase (Tdp1) inhibitors and characterization of furamidine (NSC 305831) as an inhibitor of Tdp1 Nucleic Acids Res., July 26, 2007; 35(13): 4474 - 4484. [Abstract] [Full Text] [PDF]